mRNA encoding human PCCA or PCCB protein and its use

By designing mRNA molecules with specific sequences and domains, the stability and translation efficiency of mRNA are improved, and the stability and expression level of existing mRNA drugs in the treatment of propionemia are solved, achieving higher activity and longer Half-life PCC enzyme expression provides a more effective treatment plan.

CN118166004BActive Publication Date: 2024-12-03HANGZHOU JITAI LIFE TECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410591956.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-14
Publication Date
2024-12-03
Estimated Expiration
2044-05-14

AI Technical Summary

Technical Problem

Existing mRNA drugs have low stability in vivo and in vitro, difficult to meet the needs of high-level gene expression, and are complex in design, resulting in poor results in the treatment of propionemia.

Method used

A mRNA molecule containing a human PCCA or PCCB protein is designed, containing specific nucleotide sequences and domains, such as 5'UTR, 3'UTR and poly-A regions, with chemical modifications to improve the structural stability of mRNA and translation efficiency, forming PCC enzymes with higher activity and longer half-life.

Benefits of technology

In vitro cell experiments, the mRNA expression level and the activity and half-life of PCC enzymes were significantly improved, and it has good drug potential and provides a more effective treatment plan for propionemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118166004B_ABST
    Figure CN118166004B_ABST
Patent Text Reader

Abstract

The present disclosure relates to the field of biotechnology, and specifically to mRNA for encoding human PCCA or PCCB protein and its use, wherein the mRNA molecule comprises a CDS encoding human PCCA or PCCB protein, the CDS encoding human PCCA protein comprises a nucleotide sequence selected from one of SEQ ID NO:2-6 or a nucleotide sequence having at least 80% identity therewith, and the CDS encoding human PCCB protein comprises a nucleotide sequence selected from one of SEQ ID NO:8-14 or a nucleotide sequence having at least 80% identity therewith. The present disclosure provides a new RNA molecule design scheme, which achieves a higher mRNA expression amount by rationally optimizing the nucleic acid sequence of the functional region, and the assembled PCC enzyme has a higher enzyme activity and a longer half-life, so that the RNA molecule has a wide range of application prospects in the field of gene therapy for propionic acidemia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of biotechnology, and in particular to an mRNA for encoding human PCCA or PCCB protein and uses thereof. Background Art

[0002] Propionic academia (PA) is an autosomal recessive genetic disease. It is a rare organic acidemia. The defect of propionyl-CoA carboxylase (PCC) leads to the metabolic disorder of branched-chain amino acids and odd-chain fatty acids, which causes the accumulation of propionic acid and bypass metabolites in the body, causing a series of biochemical metabolic disorders and systemic damage to the brain, heart, liver, bone marrow and other systems, resulting in disability or death. At present, there is a lack of specific treatment for propionic acidemia. In the acute phase, life support and symptomatic treatment are mainly used, including limiting protein intake, intravenous rehydration and correction of acidosis, hypoglycemia and electrolyte disorders. If necessary, peritoneal dialysis or hemodialysis is required. Long-term treatment is mainly based on restricting natural protein diet, mainly limiting the intake of valine, isoleucine, threonine and methionine, and supplemented with drugs such as L-carnitine, metronidazole, and carbamylglutamate. For patients who have poor results with combined diet and drug treatment and still have repeated severe metabolic decompensation or combined with cardiomyopathy, liver transplantation can be considered.

[0003] The pathogenic genes of PA are PCCA (propionyl-CoA carboxylase subunit alpha) and PCCB (propionyl-CoA carboxylase subunit beta), which are the two subunits of the PCC enzyme. PCCA or PCCB mutations lead to a lack of propionyl-CoA carboxylase, which results in the obstruction of the conversion of propionyl-CoA to methylmalonyl-CoA, which in turn causes an abnormal increase in metabolites such as propionate and its precursors propionyl-CoA, methylcitrate and propionylglycine in the body, causing damage to the body. Since the PCC enzyme needs to be localized to the mitochondria, there is currently no approved therapy for the root cause of PA (including enzyme replacement therapy). Some drugs are in the clinical development stage, among which the development of small molecule drugs has not achieved etiological treatment, and can only focus on supplementing circulating substances and improving symptoms. As a drug molecule, mRNA has broad application prospects and unique advantages in the field of treatment. Compared with traditional DNA therapy, mRNA drugs will not introduce exogenous genomes into the host genome, thereby reducing possible safety risks. In addition, mRNA can provide immediate and regulatable protein expression, making it ideal for treating diseases caused by the deletion or mutation of specific genes.

[0004] mRNA-3927 developed by Moderna is the only mRNA therapy currently under clinical development. This therapy encapsulates two mRNAs through lipid nanoparticles, encoding two protein subunits PCCA and PCCB, respectively, to synthesize PCC enzymes for the treatment of propionic acidemia. The sequence of mRNA-3927 has been disclosed in patent WO2023287751A1. The U.S. Food and Drug Administration (FDA) has granted mRNA-3927 fast track qualification. mRNA-3927 is currently in the clinical phase I / II stage, and existing clinical results have shown early signs of efficacy, such as a significant decrease in the incidence of metabolic disorders in patients receiving treatment, indicating that mRNA technology can treat propionic acidemia by replacing intracellular proteins, providing a potential solution for patient groups facing scarce treatment options, and showing great application prospects. However, the high complexity of mRNA nucleic acid sequence design and the low in vivo and in vitro stability of mRNA drugs are difficulties that need to be solved in the development of mRNA drugs. The mRNA sequences screened from naturally occurring genomes may have certain limitations in transcriptional regulation mechanisms and translation efficiency, and cannot meet the needs of high-level gene expression. In order to improve the expression level of the protein encoded by mRNA, the sequence needs to be optimized and screened. In addition, there are a large number of mRNA degrading enzymes in the body, and there are huge differences in the degradation rates of different mRNA sequences in the same cell, and the same mRNA sequence in different cells; in vitro, mRNA drugs can easily become ineffective due to degradation, and this instability is not conducive to the storage and transportation of mRNA drugs. Therefore, designing and screening mRNA sequences with stable structures and high translation efficiency plays an important role in the research and development of mRNA drugs. Summary of the invention

[0005] In order to solve the above technical problems, the present disclosure provides an mRNA for encoding human PCCA or PCCB protein and its use. The mRNA has a stable structure, is not easily degraded and has high translation efficiency. It shows a higher mRNA expression level in in vitro cell experiments. The PCC enzyme assembled by it has higher enzyme activity and longer half-life. The mRNA has good drug potential.

[0006] In one aspect, the present disclosure provides an mRNA molecule, wherein the mRNA molecule comprises a coding region (CDS) encoding a human PCCA or PCCB protein, the CDS encoding the human PCCA protein comprises a nucleotide sequence selected from one of SEQ ID NOs: 2-6 or a nucleotide sequence having at least 80% identity thereto, and the CDS encoding the human PCCB protein comprises a nucleotide sequence selected from one of SEQ ID NOs: 8-14 or a nucleotide sequence having at least 80% identity thereto.

[0007] In some embodiments, the mRNA molecule further comprises a 5' untranslated region (5'UTR) and / or a 3' untranslated region (3'UTR); the 5'UTR comprises a nucleotide sequence selected from one of SEQ ID NOs: 16-18 or a complementary sequence thereof, or a nucleotide sequence having at least 80% identity with a nucleotide sequence of one of SEQ ID NOs: 16-18 or a complementary sequence thereof; the 3'UTR comprises a nucleotide sequence selected from one of SEQ ID NOs: 19-22 or a complementary sequence thereof, or a nucleotide sequence having at least 80% identity with a nucleotide sequence of one of SEQ ID NOs: 19-22 or a complementary sequence thereof;

[0008] Optionally, the mRNA molecule further comprises a 5' cap structure and / or a poly-A region; preferably, the poly-A region comprises 20-500 adenine nucleotides; and the 5' cap structure is selected from Cap0 cap structure, Cap1 cap structure or Cap2 cap structure.

[0009] In some embodiments, (1) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 16, a CDS as shown in SEQ ID NO: 2, and a 3'UTR as shown in SEQ ID NO: 19; or,

[0010] (2) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 2, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0011] (3) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 3, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0012] (4) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 4, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0013] (5) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 5, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0014] (6) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 6, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0015] (7) The mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 2, and a 3'UTR as shown in SEQ ID NO: 21; or,

[0016] (8) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 18, a CDS as shown in SEQ ID NO: 8, and a 3'UTR as shown in SEQ ID NO: 22; or,

[0017] (9) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 16, a CDS as shown in SEQ ID NO: 9, and a 3'UTR as shown in SEQ ID NO: 19; or,

[0018] (10) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 8, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0019] (11) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 10, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0020] (12) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 11, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0021] (13) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 12, and 3'UTR as shown in SEQ ID NO: 20; or,

[0022] (14) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 13, and 3'UTR as shown in SEQ ID NO: 20; or,

[0023] (15) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 14 and 3'UTR shown in SEQ ID NO: 20; or,

[0024] (16) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 8, and a 3'UTR as shown in SEQ ID NO: 21.

[0025] In some embodiments, the above-mentioned mRNA molecule contains at least one chemical modification, preferably, the chemical modification is selected from at least one of pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio T-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine or 5-methoxyuridine and 2'-O-methyluridine.

[0026] In another aspect, the present disclosure provides a nucleic acid composition, wherein the nucleic acid composition comprises at least one mRNA molecule encoding a human PCCA protein, and at least one mRNA molecule encoding a human PCCB protein;

[0027] Preferably, the nucleic acid composition comprises an mRNA molecule encoding a human PCCA protein and an mRNA molecule encoding a human PCCB protein, wherein the mRNA molecule encoding a human PCCA protein and the mRNA molecule encoding a human PCCB protein are the mRNA molecules described in any one of the above items;

[0028] More preferably, the nucleic acid composition comprises (1) the mRNA molecule encoding human PCCA protein and (9) the mRNA molecule encoding human PCCB protein; or,

[0029] The nucleic acid composition comprises (1) the mRNA molecule encoding human PCCA protein and (8) the mRNA molecule encoding human PCCB protein; or,

[0030] The nucleic acid composition comprises (2) the mRNA molecule encoding human PCCA protein and (10) the mRNA molecule encoding human PCCB protein; or,

[0031] The nucleic acid composition comprises (3) the mRNA molecule encoding human PCCA protein and (11) the mRNA molecule encoding human PCCB protein; or,

[0032] The nucleic acid composition comprises (4) the mRNA molecule encoding human PCCA protein and (12) the mRNA molecule encoding human PCCB protein; or,

[0033] The nucleic acid composition comprises (5) the mRNA molecule encoding human PCCA protein and (13) the mRNA molecule encoding human PCCB protein; or,

[0034] The nucleic acid composition comprises (6) the mRNA molecule encoding the human PCCA protein and (14) the mRNA molecule encoding the human PCCB protein; or,

[0035] The nucleic acid composition comprises (1) the mRNA molecule encoding human PCCA protein and (15) the mRNA molecule encoding human PCCB protein; or,

[0036] The nucleic acid composition comprises (7) the mRNA molecule encoding the human PCCA protein and (16) the mRNA molecule encoding the human PCCB protein.

[0037] In another aspect, the present disclosure provides a vector encoding any of the above-mentioned mRNA molecules.

[0038] On the other hand, the present disclosure provides a host cell comprising any of the mRNA molecules, nucleic acid compositions or vectors described above.

[0039] In another aspect, the present disclosure provides a pharmaceutical composition, wherein the pharmaceutical composition comprises any one of (1)-(4) and a pharmaceutically acceptable carrier thereof:

[0040] (1) any of the above mRNA molecules;

[0041] (2) any of the above nucleic acid compositions;

[0042] (3) any of the above vectors; or

[0043] (4) The host cell according to any one of the above items.

[0044] In another aspect, the present disclosure provides a lipid nanoparticle comprising any of the above mRNA molecules or nucleic acid compositions.

[0045] On the other hand, the present disclosure provides the use of any of the above-mentioned mRNA molecules, nucleic acid compositions, vectors, host cells, pharmaceutical compositions or lipid nanoparticles in the preparation of a medicament for preventing, treating or ameliorating propionic acidemia and / or alleviating the symptoms of metabolic disorders or metabolic disorders caused by PCC deficiency.

[0046] The beneficial effects of the present disclosure are at least as follows:

[0047] Compared with the mRNA in the prior art, the mRNA sequence disclosed in the present invention exhibits higher mRNA expression levels in in vitro cell experiments, and the assembled PCC enzyme has higher enzyme activity and longer half-life. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the specification and, together with the description, serve to explain the principles of the specification.

[0049] Figure 1 The mRNA molecular sequence of PCCA-10 is shown;

[0050] Figure 2 Shown are the results of PCC enzyme activity detection after HepG2-PCCA KO cells were transfected with mRNA encoding human PCCA and PCCB proteins. DETAILED DESCRIPTION

[0051] I. Definition and Explanation

[0052] In the present disclosure, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology related terms and laboratory operation steps used herein are terms and routine steps widely used in the corresponding fields. At the same time, in order to better understand the present disclosure, the definitions and explanations of the relevant terms are provided below. It should be understood that the present disclosure is not limited to specific methods, reagents, compounds, compositions or biological systems, and of course the above can be changed. It should also be understood that the terms used in this application are only for describing specific embodiments and are not intended to be limited.

[0053] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.

[0054] As used herein, the terms "include" and "have" and any variations thereof, are intended to cover non-exclusive inclusions. For example, a process, method, apparatus, product or device comprising a series of steps is not limited to the listed steps or modules, but may optionally include steps that are not listed, or may optionally include other steps that are inherent to these processes, methods, products or devices. The "plurality" mentioned in this disclosure refers to two or more. "And / or" describes the association relationship of associated objects, indicating that three relationships may exist. For example, A and / or B may represent: A exists alone, A and B exist at the same time, and B exists alone. The character " / " generally indicates that the previously associated objects are in an "or" relationship.

[0055] As used herein, the terms "nucleic acid", "nucleotide" and "polynucleotide" are used interchangeably to refer to deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and polymers thereof in single-stranded, double-stranded or multi-stranded form. The term includes, but is not limited to, single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers comprising purine and / or pyrimidine bases or other natural, chemically modified, biochemically modified, non-natural, synthetic or derived nucleotide bases. In some embodiments, nucleic acids may include mixtures of DNA, RNA and their analogs. The term also encompasses nucleic acids containing known analogs of natural nucleotides, which have similar binding properties to reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides. "Nucleic acid" is used interchangeably with "gene", "DNA" and "mRNA" encoded by a gene.

[0056] As used herein, the term "mRNA (messenger RNA)" refers to any polynucleotide that encodes a polypeptide or protein of interest and can be translated in vitro, in vivo, in situ or ex vivo to produce the encoded polypeptide of interest.

[0057] As used herein, the term "CDS (Coding sequence)" is a sequence that encodes a polypeptide or protein product, which produces a polypeptide or protein when expressed.

[0058] As used herein, the term "identity" refers to the ratio of the total number of mismatched nucleotides to nucleotides in a homologous region expressed as a percentage. For example, a 20 base oligonucleotide hybridizing to a homologous region (site) in a target genome having two mismatches is referred to as having 90% identity to the region.

[0059] As used herein, the term "5'UTR" generally refers to the sequence between the 5' end of the mRNA molecule and the translation start codon, which can recruit ribosome complexes and initiate the translation of mRNA. 5'UTR includes the 5'UTR region structure on the mRNA or the structure corresponds to the coding sequence on the DNA template. 5'UTR regulates post-transcriptional modification, the formation and stability of the translation initiation complex by interacting with transcription factors, ribosomes and other transcription regulatory proteins. The sequence design and optimization of this region are essential for improving the efficiency of post-transcriptional modification and protein expression. As used herein, the terms "5'UTR structure", "5'UTR", "5'UTR sequence" and "5'UTR element" are used interchangeably, and the 5'UTR sequence involved in the present disclosure has a nucleotide sequence selected from one of SEQ ID NOs: 16-18 or its complementary sequence, or a nucleotide sequence having at least 80% identity with a nucleotide sequence or its complementary sequence of one of SEQ ID NOs: 16-18.

[0060] As used herein, the term "3'UTR" refers to the sequence between the stop codon of the polypeptide coding sequence in the mRNA and the poly (A) (poly (A)) sequence. The 3'UTR can regulate the translation of the mRNA by interacting with mRNA binding proteins, miRNAs, etc. The 3'UTR includes the 3'UTR region structure on the mRNA or the structure corresponds to the coding sequence on the DNA template. It is closely related to post-transcriptional modification and mRNA stability. The sequence and structural features of the 3'UTR can affect the stability of the mRNA, the scanning of the ribosome and the formation of the translation termination complex, etc., thereby affecting the expression level of the protein. As used herein, the terms "3'UTR structure", "3'UTR", "3'UTR sequence" and "3'UTR element" are used interchangeably, and the 3'UTR has a length of 3-500 nucleotides, 5-150 nucleotides, 10-100 nucleotides, 15-90 nucleotides, or 20-70 nucleotides. The 3'UTR element involved in the present disclosure comprises a nucleotide sequence selected from one of SEQ ID NOs: 19-22 or a complementary sequence thereof, or a nucleotide sequence having at least 80% identity with a nucleotide sequence of one of SEQ ID NOs: 19-22 or a complementary sequence thereof.

[0061] As used herein, the term "complementary sequence" refers to a nucleic acid sequence that forms hydrogen bonds with another nucleic acid sequence through traditional Watson-Crick or other non-traditional types.

[0062] As used herein, the term "poly-A region" is a poly-A sequence, which includes the structure of the poly-A region on the mRNA or the structure corresponding to the coding sequence on the DNA template. The addition of the poly-A sequence contributes to the stability and transport of the mRNA, prevents its degradation, and plays an important role in the post-transcriptional modification process. The poly-A region sequence can be a continuous chain of pure adenine nucleotides, or it can contain non-adenine nucleotides. In any form, as long as its function is equivalent to that of a traditional poly-A sequence, that is, it can provide biological functions similar to those of a traditional poly-A sequence, such as affecting the stability of mRNA, translation efficiency, or ribosome binding, the sequence is identified as a poly-A sequence. This includes, but is not limited to, known variants such as the human growth hormone (hGH) poly-A sequence and the simian virus 40 (SV40) poly-A sequence, which may differ in nucleotide composition but are functionally identified as equivalent to traditional poly-A sequences. In the present disclosure, the poly-A region sequence comprises 20-500 adenine nucleotides, for example, 25, 50, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 175, 180, 190, 200, 210, 220, 230, 240, 250, 300, 350, 400, 450 or 500 adenine nucleotides.

[0063] As used herein, the meaning of the term "5' cap structure" includes 5' cap structures and analogs thereof present on natural mRNA. The 5' cap structure on natural mRNA refers to that methylated guanylate is connected to the 5' terminal nucleotide of RNA via pyrophosphate to form a 5', 5'-triphosphate connection (5', 5'-triphosphate linkage). There are three types of 5' cap structures (m7G5'ppp5'Np, m7G5'ppp5'NmpNp, m7G5'ppp5'NmpNmpNp), which are respectively referred to as Cap0, Cap1 and Cap2. Cap0 refers to that the ribose of the terminal nucleotide is not methylated, Cap1 refers to that the ribose of one nucleotide at the end is methylated, and Cap2 refers to that the ribose of the two nucleotides at the end is methylated. Methods for capping mRNA molecules are known in the art. The 5' cap structure of the aforementioned mRNA molecule can be added by enzymatic reaction after obtaining the mRNA molecule by chemical synthesis or in vitro transcription (for example, by a commercial kit comprising vaccinia capping enzyme and mRNA cap structure 2'-O-methyltransferase). However, capped mRNA can also be produced by incorporating a capping nucleotide analog directly as the first nucleotide into the transcript during in vitro transcription.

[0064] As used herein, the term "chemical modification" or "chemically modified" refers to a modification of one or more of the position, pattern, percentage or population of adenosine (A), guanosine (G), uridine (U) or cytidine (C) ribonucleosides or deoxyribonucleosides. In this article, these terms are not intended to refer to ribonucleotide modifications in naturally occurring 5' cap structures.

[0065] As used herein, the term "pharmaceutically acceptable carrier" refers to one or more compatible solid, semisolid, liquid or gel fillers that are suitable for human or animal use and must have sufficient purity and sufficiently low toxicity. "Compatibility" refers to the components in the pharmaceutical composition and the active ingredients of the drug and their mutual blending without significantly reducing the efficacy. In the present invention, the aforementioned pharmaceutically acceptable carrier includes but is not limited to a buffer, an excipient, a stabilizer or a preservative. Examples of pharmaceutically acceptable carriers are physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delaying agents, such as salts, buffers, sugars, antioxidants, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants or emulsifiers or combinations thereof. The amount of a pharmaceutically acceptable carrier in a pharmaceutical composition can be determined experimentally based on the activity of the carrier and the desired properties of the formulation, such as stability and / or minimal oxidation.

[0066] As used herein, the term "lipid nanoparticle" refers to a particle containing lipid components and having nanometer-scale dimensions.

[0067] As used herein, the term "ionizable cationic lipid" refers to a lipid molecule that can be positively charged under physiological pH conditions. For example, the ionizable cationic lipid is an amino lipid.

[0068] As used herein, the term "neutral lipid" refers to a lipid molecule that is uncharged under specific pH conditions, such as physiological pH conditions. Examples of neutral lipids include, but are not limited to, one or more of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), preferably DSPC and / or DOPE.

[0069] As used herein, the term "structured lipid" refers to a lipid that fills the gaps between lipids to enhance the stability of nanoparticles, such as steroids. Steroids are compounds with a cyclopentane pyrophenanthrene carbon skeleton. In a preferred embodiment, the steroid is selected from one or more of cholesterol, sitosterol, coprosterol, saposterol, brassicasterol, ergosterol, tomatine, ursolic acid, α-tocopherol, stigmasterol, avenasterol, ergocalciferol or campesterol, preferably cholesterol and / or β-sitosterol, more preferably cholesterol.

[0070] As used herein, the term "polymer lipid" refers to a molecule containing a polymer portion and a lipid portion. In some embodiments, the polymer lipid is a polyethylene glycol (PEG) lipid. Other lipids that can reduce aggregation, such as products of lipid coupling with compounds having uncharged, hydrophilic, steric barrier portions, can also be used. In a preferred embodiment, the PEGylated lipid is selected from: one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol. Optionally, the PEGylated lipid contains a PEG portion of about 1000Da to about 20kDa, preferably a PEG portion of about 1000Da to about 5000Da. Optionally, the PEGylated lipid is selected from one or more of DMPE-PEG1000, DPPE-PEG1000, DSPE-PEG1000, DOPE-PEG1000, DMG-PEG2000, Ceramide-PEG2000, DMPE-PEG2000, DPPE-PEG2000, DSPE-PEG2000, Azido-PEG2000, DSPE-PEG2000-Mannose, Ceramide-PEG5000, and DSPE-PEG5000, preferably DMG-PEG2000.

[0071] As used herein, the term "vector" refers to a section of DNA extracted from a virus, plasmid or a cell of a higher organism, into which a foreign DNA fragment can be inserted or has been inserted for cloning and / or expression purposes. In certain embodiments, the vector can be stably maintained in an organism. The vector may include, for example, an origin of replication, a selective marker or a reporter gene, such as antibiotic resistance or GFP, and / or a multiple cloning site (MCS). The term includes linear DNA fragments (e.g., PCR products, linear plasmid fragments), plasmid vectors, viral vectors, cosmids, bacterial artificial chromosomes (BAC), yeast artificial chromosomes (YAC), etc.

[0072] As used herein, the terms "cell" and "host cell" are used interchangeably in the present invention and refer to cells that express or are capable of expressing a sequence to be expressed. The host cells of the present invention express polynucleotides encoding polypeptides or RNAs with a variety of uses, including biotechnology, molecular biology, and clinical applications. Host cells include prokaryotic cells or eukaryotic cells, and examples of suitable host cells in the present invention include, but are not limited to, bacteria, yeast cells, insect cells, animal cells, and mammalian cells.

[0073] II. Detailed description of specific implementation plan

[0074] In one aspect, the present disclosure provides an mRNA molecule, wherein the mRNA molecule comprises a CDS encoding a human PCCA or PCCB protein, the CDS encoding a human PCCA protein comprises a nucleotide sequence selected from one of SEQ ID NOs: 2-6 or a nucleotide sequence having at least 80% identity thereto, and the CDS encoding a human PCCB protein comprises a nucleotide sequence selected from one of SEQ ID NOs: 8-14 or a nucleotide sequence having at least 80% identity thereto.

[0075] In some embodiments, the mRNA molecule further comprises a 5'UTR and / or a 3'UTR; the 5'UTR comprises a nucleotide sequence selected from one of SEQ ID NOs: 16-18 or a complementary sequence thereof, or a nucleotide sequence having at least 80% identity with a nucleotide sequence of one of SEQ ID NOs: 16-18 or a complementary sequence thereof; the 3'UTR comprises a nucleotide sequence selected from one of SEQ ID NOs: 19-22 or a complementary sequence thereof, or a nucleotide sequence having at least 80% identity with a nucleotide sequence of one of SEQ ID NOs: 19-22 or a complementary sequence thereof;

[0076] Optionally, the mRNA molecule further comprises a 5' cap structure and / or a poly-A region; preferably, the poly-A region comprises 20-500 adenine nucleotides; and the 5' cap structure is selected from Cap0 cap structure, Cap1 cap structure or Cap2 cap structure.

[0077] In some optional embodiments, the above-mentioned 3'UTR sequence further comprises a 3'UTR sequence or its complementary sequence inserted with an additional sequence; preferably, the additional sequence is a miRNA binding site; more preferably, the additional sequence is selected from the full-length microRNA reverse complementary sequence or the reverse complementary sequence of its seed sequence; preferably, the full-length microRNA reverse complementary sequence is 19-25 nt in length; preferably, the reverse complementary sequence of the seed sequence is 7-8nt in length; preferably, the aforementioned 3'UTR sequence further comprises a 3'UTR sequence or its complementary sequence inserted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 additional sequences.

[0078] In some optional embodiments, the poly-A sequence comprises 25, 50, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 175, 180, 190, 200, 210, 220, 230, 240, 250, 300, 350, 400, 450 or 500 adenine nucleotides (A); preferably 120 adenine nucleotides, specifically the poly-A region sequence shown in SEQ ID NO:15.

[0079] In some optional embodiments, the 5' cap structure is preferably a Cap1 cap structure.

[0080] In some embodiments, (1) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 16, a CDS as shown in SEQ ID NO: 2, and a 3'UTR as shown in SEQ ID NO: 19; or,

[0081] (2) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 2, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0082] (3) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 3, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0083] (4) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 4, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0084] (5) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 5, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0085] (6) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 6, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0086] (7) The mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 2, and a 3'UTR as shown in SEQ ID NO: 21; or,

[0087] (8) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 18, a CDS as shown in SEQ ID NO: 8, and a 3'UTR as shown in SEQ ID NO: 22; or,

[0088] (9) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 16, a CDS as shown in SEQ ID NO: 9, and a 3'UTR as shown in SEQ ID NO: 19; or,

[0089] (10) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 8, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0090] (11) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 10, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0091] (12) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 11, and a 3'UTR as shown in SEQ ID NO: 20; or,

[0092] (13) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 12, and 3'UTR as shown in SEQ ID NO: 20; or,

[0093] (14) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 13, and 3'UTR as shown in SEQ ID NO: 20; or,

[0094] (15) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 14 and 3'UTR shown in SEQ ID NO: 20; or,

[0095] (16) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 8, and a 3'UTR as shown in SEQ ID NO: 21.

[0096] In some embodiments, (I-1) the above mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a Cap1 cap structure, a 5'UTR as shown in SEQ ID NO: 16, a CDS as shown in SEQ ID NO: 2, a 3'UTR as shown in SEQ ID NO: 19, and a poly-A region as shown in SEQ ID NO: 15; or,

[0097] (I-2) the mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 2, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0098] (I-3) The mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 3, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0099] (I-4) The mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 4, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0100] (I-5) The mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 5, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0101] (I-6) The mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 6, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0102] (I-7) The mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 2, 3'UTR shown in SEQ ID NO: 21 and poly-A region shown in SEQ ID NO: 15; or,

[0103] (I-8) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 18, CDS shown in SEQ ID NO: 8, 3'UTR shown in SEQ ID NO: 22 and poly-A region shown in SEQ ID NO: 15; or,

[0104] (I-9) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 16, CDS shown in SEQ ID NO: 9, 3'UTR shown in SEQ ID NO: 19 and poly-A region shown in SEQ ID NO: 15; or,

[0105] (I-10) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 8, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0106] (I-11) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 10, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0107] (I-12) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 11, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0108] (I-13) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 12, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0109] (I-14) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 13, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0110] (I-15) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 14, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15; or,

[0111] (I-16) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:17, CDS shown in SEQ ID NO:8, 3'UTR shown in SEQ ID NO:21 and poly-A region shown in SEQ ID NO:15.

[0112] In some embodiments, the above-mentioned mRNA molecule contains at least one chemical modification, and the chemical modification is selected from at least one of pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio T-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine or 5-methoxyuridine and 2'-O-methyluridine; preferably N1-methylpseudouridine.

[0113] In some embodiments, the uracil in the above-mentioned mRNA molecule has a chemical modification; in some embodiments, the chemical modification is located at the 5-position of uracil; preferably, the chemical modification is N1-methylpseudouridine; more preferably, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% of the uracil in the above-mentioned mRNA molecule has a chemical modification, and the chemical modification is N1-methylpseudouridine.

[0114] In some embodiments, the above-mentioned mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in order from 5' to 3', 5'UTR, CDS encoding human PCCA protein and 3'UTR, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; preferably, the above-mentioned mRNA molecule comprises, in order from 5' to 3', 5'cap structure, 5'UTR, CDS encoding human PCCA protein, 3'UTR and poly-A region, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine.

[0115] In some embodiments, the above mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in order from 5' to 3', 5'UTR, CDS encoding human PCCB protein and 3'UTR, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; preferably, the above mRNA molecule comprises, in order from 5' to 3', 5'cap structure, 5'UTR, CDS encoding human PCCB protein, 3'UTR and poly-A region, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine.

[0116] In some embodiments, (II-1) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a Cap1 cap structure, a 5'UTR as shown in SEQ ID NO: 16, a CDS as shown in SEQ ID NO: 2, a 3'UTR as shown in SEQ ID NO: 19, and a poly-A region as shown in SEQ ID NO: 15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0117] (II-2) the mRNA molecule is an mRNA molecule 9 encoding a human PCCA protein, which comprises, in 5' to 3' order: a Cap1 cap structure, a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 2, a 3'UTR as shown in SEQ ID NO: 20, and a poly-A region as shown in SEQ ID NO: 15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0118] (II-3) the mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 3, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0119] (II-4) the mRNA molecule is an mRNA molecule encoding a human PCCA protein, which comprises, in 5' to 3' order: a Cap1 cap structure, a 5'UTR as shown in SEQ ID NO: 17, a CDS as shown in SEQ ID NO: 4, a 3'UTR as shown in SEQ ID NO: 20, and a poly-A region as shown in SEQ ID NO: 15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0120] (II-5) the mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 5, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0121] (II-6) the mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 6, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15, and 100% of uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0122] (II-7) the mRNA molecule is an mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 2, 3'UTR shown in SEQ ID NO: 21 and poly-A region shown in SEQ ID NO: 15, and 100% of uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0123] (II-8) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:18, CDS shown in SEQ ID NO:8, 3'UTR shown in SEQ ID NO:22 and poly-A region shown in SEQ ID NO:15, and 100% of uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0124] (II-9) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:16, CDS shown in SEQ ID NO:9, 3'UTR shown in SEQ ID NO:19 and poly-A region shown in SEQ ID NO:15, and 100% of uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0125] (II-10) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 8, 3'UTR shown in SEQ ID NO: 20 and poly-A region shown in SEQ ID NO: 15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0126] (II-11) the mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:17, CDS shown in SEQ ID NO:10, 3'UTR shown in SEQ ID NO:20 and poly-A region shown in SEQ ID NO:15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0127] (II-12) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:17, CDS shown in SEQ ID NO:11, 3'UTR shown in SEQ ID NO:20 and poly-A region shown in SEQ ID NO:15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0128] (II-13) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:17, CDS shown in SEQ ID NO:12, 3'UTR shown in SEQ ID NO:20 and poly-A region shown in SEQ ID NO:15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0129] (II-14) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:17, CDS shown in SEQ ID NO:13, 3'UTR shown in SEQ ID NO:20 and poly-A region shown in SEQ ID NO:15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0130] (II-15) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:17, CDS shown in SEQ ID NO:14, 3'UTR shown in SEQ ID NO:20 and poly-A region shown in SEQ ID NO:15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine; or,

[0131] (II-16) The mRNA molecule is an mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: Cap1 cap structure, 5'UTR shown in SEQ ID NO:17, CDS shown in SEQ ID NO:8, 3'UTR shown in SEQ ID NO:21 and poly-A region shown in SEQ ID NO:15, and 100% of the uracil in the mRNA molecule is N1-methylpseudouridine.

[0132] In another aspect, the present disclosure provides a nucleic acid composition, wherein the nucleic acid composition comprises at least one mRNA molecule encoding a human PCCA protein, and at least one mRNA molecule encoding a human PCCB protein;

[0133] Preferably, the nucleic acid composition comprises an mRNA molecule encoding a human PCCA protein and an mRNA molecule encoding a human PCCB protein, wherein the mRNA molecule encoding a human PCCA protein and the mRNA molecule encoding a human PCCB protein are the mRNA molecules described in any one of the above items;

[0134] More preferably, the nucleic acid composition comprises the mRNA molecule encoding human PCCA protein described in (1) above and the mRNA molecule encoding human PCCB protein described in (9) above; or

[0135] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (1) above and the mRNA molecule encoding the human PCCB protein described in (8) above; or,

[0136] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (2) above and the mRNA molecule encoding the human PCCB protein described in (10) above; or,

[0137] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (3) above and the mRNA molecule encoding the human PCCB protein described in (11) above; or

[0138] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (4) above and the mRNA molecule encoding the human PCCB protein described in (12) above; or,

[0139] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (5) above and the mRNA molecule encoding the human PCCB protein described in (13) above; or,

[0140] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (6) above and the mRNA molecule encoding the human PCCB protein described in (14) above; or,

[0141] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (1) above and the mRNA molecule encoding the human PCCB protein described in (15) above; or,

[0142] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (7) above and the mRNA molecule encoding the human PCCB protein described in (16) above.

[0143] More preferably, the nucleic acid composition comprises the mRNA molecule encoding human PCCA protein described in (I-1) above and the mRNA molecule encoding human PCCB protein described in (I-9) above; or,

[0144] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (I-1) above and the mRNA molecule encoding the human PCCB protein described in (I-8) above; or,

[0145] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (I-2) above and the mRNA molecule encoding the human PCCB protein described in (I-10) above; or,

[0146] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (I-3) above and the mRNA molecule encoding the human PCCB protein described in (I-11) above; or,

[0147] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (I-4) above and the mRNA molecule encoding the human PCCB protein described in (I-12) above; or,

[0148] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (I-5) above and the mRNA molecule encoding the human PCCB protein described in (I-13) above; or,

[0149] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (I-6) above and the mRNA molecule encoding the human PCCB protein described in (I-14) above; or,

[0150] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (I-1) above and the mRNA molecule encoding the human PCCB protein described in (I-15) above; or,

[0151] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (I-7) above and the mRNA molecule encoding the human PCCB protein described in (I-16) above.

[0152] More preferably, the nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-1) above and the mRNA molecule encoding the human PCCB protein described in (II-9) above; or,

[0153] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-1) above and the mRNA molecule encoding the human PCCB protein described in (II-8) above; or,

[0154] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-2) above and the mRNA molecule encoding the human PCCB protein described in (II-10) above; or,

[0155] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-3) above and the mRNA molecule encoding the human PCCB protein described in (II-11) above; or,

[0156] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-4) above and the mRNA molecule encoding the human PCCB protein described in (II-12) above; or,

[0157] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-5) above and the mRNA molecule encoding the human PCCB protein described in (II-13) above; or,

[0158] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-6) above and the mRNA molecule encoding the human PCCB protein described in (II-14) above; or,

[0159] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-1) above and the mRNA molecule encoding the human PCCB protein described in (II-15) above; or,

[0160] The nucleic acid composition comprises the mRNA molecule encoding the human PCCA protein described in (II-7) above and the mRNA molecule encoding the human PCCB protein described in (II-16) above.

[0161] In some preferred embodiments, the molar ratio of the mRNA molecule encoding human PCCA protein to the mRNA molecule encoding human PCCB protein is 1:0.1-10.

[0162] In some preferred embodiments, the molar ratio of the mRNA molecule encoding human PCCA protein to the mRNA molecule encoding human PCCB protein is selected from 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10; preferably, the molar ratio of the mRNA molecule encoding human PCCA protein to the mRNA molecule encoding human PCCB protein is 1:1.

[0163] In another aspect, the present disclosure provides a vector encoding any of the above-mentioned mRNA molecules.

[0164] On the other hand, the present disclosure provides a host cell comprising any of the mRNA molecules, nucleic acid compositions or vectors described above.

[0165] In another aspect, the present disclosure provides a pharmaceutical composition, wherein the pharmaceutical composition comprises any one of (1)-(4) and a pharmaceutically acceptable carrier thereof:

[0166] (1) any of the above mRNA molecules;

[0167] (2) any of the above nucleic acid compositions;

[0168] (3) any of the above vectors; or

[0169] (4) The host cell according to any one of the above items.

[0170] In another aspect, the present disclosure provides a lipid nanoparticle comprising any of the above mRNA molecules or nucleic acid compositions.

[0171] In some preferred embodiments, the lipid nanoparticles further comprise one or more lipid moieties, wherein the one or more lipid moieties are selected from the group consisting of ionizable cationic lipids, structural lipids, neutral lipids or polymer lipids.

[0172] On the other hand, the present disclosure provides the use of any of the above-mentioned mRNA molecules, nucleic acid compositions, vectors, host cells, pharmaceutical compositions or lipid nanoparticles in the preparation of a medicament for preventing, treating or ameliorating propionic acidemia and / or alleviating the symptoms of metabolic disorders or metabolic disorders caused by PCC deficiency.

[0173] In some preferred embodiments, the metabolic disorders or metabolic disorder symptoms caused by PCC deficiency include electrolyte imbalance, dehydration, hypoglycemia, rash, muscle spasm, brain damage, coma, vision loss, osteoporosis, epilepsy or stroke.

[0174] For purposes of clarity and concise description, features are described herein as part of the same or separate embodiments, however, it will be understood that the scope of the present disclosure may include embodiments having a combination of all or some of the described features.

[0175] Example

[0176] Example 1: mRNA sequences encoding PCCA and PCCB proteins

[0177] For wild-type human PCCA and PCCB proteins (the amino acid sequence of wild-type human PCCA protein is such as SEQ ID NO: 1, and the amino acid sequence of wild-type human PCCB protein is such as SEQ ID NO: 7), different optimization algorithms such as CDSfold and Ribotree are used to optimize stability and translation efficiency, and design some mRNA sequences. These mRNA sequences are obtained by gene synthesis, in vitro transcription template preparation, plasmid linearization, IVT mRNA synthesis, purification and quality inspection, etc., and are used for in vitro cell experiments. The final mRNA molecular sequence is shown in Table 1, and all uracils in the mRNA molecular sequence are N1-methylpseudouridine; for example, the mRNA molecular sequence of PCCA-10 is shown in Figure 1 , all uracils in the mRNA molecular sequence of PCCA-10 are N1-methyl pseudouridine. Among them, the present application uses PCCA-06 and PCCB-06 as controls, which are derived from the mRNA-3927 sequence disclosed in patent WO2023287751A1.

[0178] Table 1 mRNA sequences encoding human PCCA and PCCB proteins

[0179]

[0180] Example 2: Protein expression and enzyme activity detection after transfection of HepG2 with mRNA encoding human PCCA and PCCB proteins

[0181] The mRNA obtained in Example 1 was used in an in vitro cell experiment to test the protein expression levels of human PCCA and PCCB and the PCC enzyme activity level.

[0182] The specific experimental procedures for determining the protein expression levels of PCCA and PCCB and the PCC enzyme activity level are as follows:

[0183] Human hepatoma cell HepG2 (Cat. No.: SCSP-510, purchased from the Cell Bank of the Chinese Academy of Sciences) was cultured in DMEM high-glucose medium containing 10% fetal bovine serum at 37°C and 5% CO2 until the cell density was above 90%. 24 h before transfection, HepG2 cells were counted using a cell counter (Brand: BroadBody; Model: JSY-FL-049) and seeded in 24-well plates at a density of 1.5×105 cells / well, with 500 μL of culture medium per well.

[0184] After 24 hours, Lipofectamine MessengerMAX (Brand: Thermo Fisher Scientific; Catalog No.: LMRNA008; Batch No.: 2646532) was used to transfect mRNA (mRNA information is shown in Tables 1 and 2), and PCCA and PCCB were co-transfected with 500ng mRNA at a molar ratio of 1:1 (i.e., PCCA 286ng, PCCB 214ng). The negative control ctrl group was not transfected with mRNA. The single-hole transfection system is as follows:

[0185] Solution A: 25µL Opti-MEM + 1.5µL Lipofectamine MessengerMAX, incubate at room temperature for 5 minutes;

[0186] Solution B: 25µL Opti-MEM + 500ng mRNA, incubate at room temperature for 5min;

[0187] A+B was allowed to stand at room temperature for 20 minutes.

[0188] Slowly add 450µL opti-MEM to 50µL of the mixed transfection solution, mix thoroughly and drop into the culture plate. After 4 hours, remove the transfection medium and add 1mL complete medium to continue culturing.

[0189] Samples were collected 48h, 96h, and 144h after transfection, and 500 μL of lysis buffer (RIPA (strong): PMSF: cocktail = 100:1:4) was added to one sample well for lysis. The total protein concentration was quantified using a BCA kit (brand: BioTek; item number: P0009; batch number: 092822221121), and then PCCA and PCCB ELISA kits (PCCA ELISA kit (brand: Abbexa Ltd; item number: abx585094; batch number: E2212484W); PCCB ELISA kit (brand: Wuhan Finn; item number: EH0800; batch number: H0800I072P)) were used for detection, and the protein expression level was measured using an enzyme reader (brand: BioTek; model: SYNERGY H1), see Table 2. At the same time, 48h and 144h samples were collected, 100 μL of lysis solution (RIPA (strong): PMSF: cocktail = 100: 1: 4) was added to each sample well, lysed on ice for 30 min, and centrifuged at 12000 rpm for 15 min. The total protein concentration of the supernatant was quantified to 0.5 mg / mL on the same day, and the enzyme activity was detected by HPLC, as shown in Table 3. Compared with mRNA-3927 (PCCA-06 + PCCB-06), the mRNA sequence disclosed in the present invention has significantly higher protein expression levels and enzyme activity levels.

[0190] Table 2 PCCA and PCCB protein ELISA test results

[0191]

[0192] Table 3 PCC enzyme activity test results

[0193]

[0194] Example 3: Enzyme activity detection after transfection of HepG2-PCCA KO cells with mRNA encoding human PCCA and PCCB proteins

[0195] A PCCA gene knockout HepG2 cell line (HepG2-PCCA KO, customized by Shanghai Yuanjing Biological) was constructed. In the absence of PCC background enzyme activity in HepG2-PCCA KO cells, the enzyme activity levels after co-transfection of PCCA and PCCB mRNA were tested.

[0196] The mRNAs used were PCCA-06, PCCA-10, PCCA-31, PCCB-06, PCCB-31, and PCCB-38.

[0197] The specific experimental process is as follows:

[0198] HepG2-PCCA KO cells were cultured in DMEM high-glucose medium containing 10% fetal bovine serum at 37°C and 5% CO2 until the cell density reached more than 90%. 24 h before transfection, the cells were counted using a cell counter (brand: BroadBio; model: JSY-FL-049) and seeded in 24-well plates at a density of 1.5×105 cells / well, with 500 μL of culture medium per well.

[0199] After 24 hours, Lipofectamine MessengerMAX was used to transfect mRNA PCCA and PCCB in a molar ratio of 1:1 to co-transfect 500ng mRNA (i.e. PCCA 286ng, PCCB 214ng). The negative control ctrl group was not transfected with mRNA. The single-hole transfection system is as follows:

[0200] Solution A: 25µL Opti-MEM + 1.5µL Lipofectamine MessengerMAX, incubate at room temperature for 5 minutes;

[0201] Solution B: 25µL Opti-MEM + 500ng mRNA, incubate at room temperature for 5min;

[0202] A+B was allowed to stand at room temperature for 20 minutes.

[0203] Slowly add 50µL of the mixed transfection solution to 450µL opti-MEM, mix thoroughly and drop into the culture plate. After 4 hours, remove the transfection medium and add 1mL of complete medium (FBS concentration 15%) to continue culturing.

[0204] Samples were collected 2d, 4d, 7d, 9d, and 11d after transfection. 100µL of lysis buffer (RIPA (strong): PMSF: cocktail = 100: 1: 4) was added to each sample well. After lysis on ice for 30min, the cells were centrifuged at 12000rpm*15min. The total protein concentration was quantified to 0.5mg / mL and the enzyme activity was detected by HPLC. The AUC and half-life were calculated by Phoenix software. The PCC enzyme activity generated by different mRNA combinations was compared. The test results are shown in Figure 2 , Table 4 and Table 5.

[0205] Table 4 PCC enzyme activity test results

[0206]

[0207] Table 5 PCC enzyme AUC and T1 / 2 calculation results

[0208]

[0209] Figure 2 The results of Tables 4 and 5 show that in the absence of PCC background enzyme activity in HepG2-PCCA KO cells, the expression of PCC enzyme activity can be detected after PCCA and PCCB mRNA transfection. Compared with mRNA-3927 (PCCA-06+PCCB-06), the mRNA sequence combinations PCCA-10+PCCB-31, PCCA-10+PCCB-38, and PCCA-31+PCCB-31 disclosed in the present invention have significantly higher enzyme activity levels at each detection time point, and higher AUC. Among them, PCCA-10+PCCB-38 also has a significantly longer half-life.

Claims

1. A nucleic acid composition, the nucleic acid composition consisting of an mRNA molecule encoding a human PCCA protein and an mRNA molecule encoding a human PCCB protein; wherein: (1) the mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO:16, CDS as shown in SEQ ID NO:2, and 3'UTR as shown in SEQ ID NO:19; and the mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO:18, CDS as shown in SEQ ID NO:8, and 3'UTR as shown in SEQ ID NO:22; or, (2) the mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 16, CDS as shown in SEQ ID NO: 2, and 3'UTR as shown in SEQ ID NO: 19; and the mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 16, CDS as shown in SEQ ID NO: 9, and 3'UTR as shown in SEQ ID NO: 19; or, (3) the mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 2, and 3'UTR as shown in SEQ ID NO: 20; and the mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 8, and 3'UTR as shown in SEQ ID NO: 20; or, (4) the mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 3, and 3'UTR as shown in SEQ ID NO: 20; and the mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 10, and 3'UTR as shown in SEQ ID NO: 20; or, (5) the mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: the 5'UTR of SEQ ID NO: 17, the CDS of SEQ ID NO: 4, and the 3'UTR of SEQ ID NO: 20; and the mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: the 5'UTR of SEQ ID NO: 17, the CDS of SEQ ID NO: 11, and the 3'UTR of SEQ ID NO: 20; or, (6) the mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 5, and 3'UTR as shown in SEQ ID NO: 20; and the mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 12, and 3'UTR as shown in SEQ ID NO: 20; or, (7) the mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 6, and 3'UTR as shown in SEQ ID NO: 20; and the mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 13, and 3'UTR as shown in SEQ ID NO: 20; or, (8) The mRNA molecule encoding human PCCA protein comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 16, CDS as shown in SEQ ID NO: 2, and 3'UTR as shown in SEQ ID NO: 19; and the mRNA molecule encoding human PCCB protein comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 14, and 3'UTR as shown in SEQ ID NO: 20; or, (9) The mRNA molecule encoding human PCCA protein comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 2, and 3'UTR as shown in SEQ ID NO: 21; and the mRNA molecule encoding human PCCB protein comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 8, and 3'UTR as shown in SEQ ID NO: 21; or, (10) The mRNA molecule encoding human PCCA protein comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 16, CDS as shown in SEQ ID NO: 2, and 3'UTR as shown in SEQ ID NO: 19; and the mRNA molecule encoding human PCCB protein comprises, in 5' to 3' order: 5'UTR as shown in SEQ ID NO: 17, CDS as shown in SEQ ID NO: 10, and 3'UTR as shown in SEQ ID NO: 20; or, (11) The mRNA molecule encoding human PCCA protein, which comprises, in 5' to 3' order: 5'UTR shown in SEQ ID NO: 16, CDS shown in SEQ ID NO: 2, and 3'UTR shown in SEQ ID NO: 19; and the mRNA molecule encoding human PCCB protein, which comprises, in 5' to 3' order: 5'UTR shown in SEQ ID NO: 17, CDS shown in SEQ ID NO: 8, and 3'UTR shown in SEQ ID NO: 21; and, The mRNA molecule further comprises a chemical modification, wherein all uracils in the mRNA molecule are replaced with N1-methyl pseudouridine.

2. The nucleic acid composition according to claim 1, wherein The mRNA molecule further comprises a 5' cap structure and / or a poly-A region.

3. The nucleic acid composition according to claim 2, wherein The poly-A region of the mRNA molecule comprises 20-500 adenine nucleotides; and / or the 5' cap structure of the mRNA molecule is selected from Cap0 cap structure, Cap1 cap structure or Cap2 cap structure.

4. The nucleic acid composition according to claim 3, wherein The 5' cap structure of the mRNA molecule is a Cap1 cap structure; and / or the nucleotide sequence of the poly-A region is as shown in SEQ ID NO:

15.

5. A vector comprising the nucleic acid composition according to any one of claims 1 to 4. 6 . A host cell comprising the nucleic acid composition according to claim 1 , or the vector according to claim 5 .

7. A pharmaceutical composition, wherein The pharmaceutical composition comprises any one of (1)-(3) and a pharmaceutically acceptable carrier thereof: (1) The nucleic acid composition according to any one of claims 1 to 4; (2) the vector according to claim 5; or (3) The host cell according to claim 6.

8. A lipid nanoparticle comprising the nucleic acid composition according to any one of claims 1 to 4.

9. Use of the nucleic acid composition of any one of claims 1 to 4, the vector of claim 5, the host cell of claim 6, the pharmaceutical composition of claim 7 or the lipid nanoparticle of claim 8 in the preparation of a medicament for preventing, treating or ameliorating propionic acidemia caused by PCC deficiency.